Abstracts
Purpose: Infl ammatory bowel diseases are signifi cant problems in the United States and developed countries. It has become more recognized in patients of other ethnicities, such as African American, Hispanic and Asian although it may be under-recognized and under-reported. In this retrospective descriptive study, we tried to assess the characteristics of incarcerated patients who present to the state hospital with a known diagnosis or symptoms of infl ammatory bowel disease. We also tried to determine how these patients are being treated and if the recommended health maintenance is followed. Methods: Retrospective study of department of correction patients who were seen in a GI clinic at University of Connecticut from 10/01/2001 to 10/01/2011. All patients with IBD aged 18 and above were included, while pregnant, breastfeeding patients and patients younger than 18 were excluded. Demographic data were collected and analyzed. Categorical variables were expressed in percentages, and continuous variables were expressed as means. Results: 93 incarcerated patients with IBD were seen in the GI clinic during the defined period, but only 65 charts were included due to incomplete data on the others. 64 patients were male with only one female, 26 had Crohn's disease (40%), 35 had ulcerative colitis (40%), and four had indeterminate colitis (6%). More than two thirds of patients (72%) were initially diagnosed after incarceration. More than half were Caucasian (54%), while the rest were African Americans (28%), Hispanics (18%) and others. A significant number have co-existing hepatitis C (15%). Low levels of 25 hydroxyvitamin D were seen in eight patients, but an overwhelming number of patients (80%) were not tested for vitamin D levels. Majority of patients were recommended to have DEXA scans done, but only one patient had the test performed. A vast majority of patients (94%) were managed with 5-ASA. In addition to 5-ASA, patients were given steroids (78%), 6-MP (37%), infliximab (15%), azathioprine (8%), and only 1.5% were given cyclosporine, methotrexate, natalizumab, adalimumab, certulizumab. Conclusion: The majority of individuals who enter the department of corrections with symptoms of IBD are diagnosed after incarceration. This can be explained in part by the lack of access to health providers prior to the incarceration. Their entry into the system allows them access to healthcare via the state hospital, and ensures close follow up. The composition of patients shows a disproportionately large group of non-Caucasians (46%), although the total number of prisoners are unknown to us. Many of these patients were treated with immunomodulators, which may indicate more severe disease in the population. Routine health maintenance also needs to be addressed in more patients.
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Pseudomembraneous Negative Clostridium diffi cile Colitis in Patients with Infl ammatory Bowel Disease Undergoing Colonoscopy: Retrospective Review
Muhammad Bawany, MD, William Sodeman, MD, Ehsan Rafi q, MD, Muhammad Khan, MD, Ali Nawras, MD, FACG. Internal Medicine, University of Toledo Medical Center, Toledo, OH. Purpose: Patients with inflammatory bowel disease have increased risk of developing Clostridium difficile infection. According to registry database, 10% of inflammatory bowel disease patients will develop a Clostridium difficile infection at some point in their lifetime. Rates of Clostridium difficile infection among inflammatory bowel disease patients appear to be increasing in some institutions. A high index of suspicion and prompt diagnosis is required when evaluating inflammatory bowel disease patients with apparent relapse, to rule out coexisting Clostridium difficile colitis. According to some reports, endoscopic and biopsy findings in inflammatory bowel disease patients with Clostridium difficile infection do not reveal features of pseudomembranous colitis. Objective: The aim of this study is to review the incidence of endoscopic and pathological features of pseudomembranous colitis in patients with coexisting inflammatory bowel disease and Clostridium difficile infection. Methods: We carried out a chart review of patients with history of infl ammatory bowel disease (ulcerative colitis and Chron's colitis) with symptoms and signs of exacerbation of the disease, who had undergone colonoscopy (with stool aspirate and biopsy) as part of their work-up between October, 2009 and September, 2012 . Th e demographic characteristics, type of infl ammatory bowel disease, colonoscopy fi ndings, biopsies, and stool aspirates were analyzed. Results: A total of 93 infl ammatory bowel disease patients who had undergone colonoscopy (with stool aspirate and biopsy) for infl ammatory bowel disease-related symptoms were identifi ed. Out of the 93 patients, endoscopy fi ndings revealed signs of infl ammation (ranging from erythematous mucosa to ulceration) were reported in 83 patients. Diagnosis of Clostridium diffi cile infection was confi rmed in seven of these patients, based on positive colonic stool aspirate for Clostridium diffi cile toxin. None of these seven patients had endoscopic or histological features of pseudomembranous colitis (Table 1) . Conclusion: Endoscopic and histological fi ndings were not helpful in making the diagnosis of Clostridium diffi cile colitis in infl ammatory bowel disease patients because of the absence of pseudomembranous features. Colonic stool aspirate was required to make the diagnosis of Clostridium diffi cile colitis in the infl ammatory bowel disease patients. Purpose: Younger age at diagnosis is associated with more aggressive phenotypes in Crohn's disease (CD) and ulcerative colitis (UC). We evaluated the eff ect of age at initial visit on disease activity and disease-specifi c quality of life over time in a tertiary referral IBD cohort. Methods: Retrospective cohort study in IBD patients identified from an IRB-approved clinical data repository from July, 2004 to July, 2012. We compared age at index visit (<40 years, 40-59 years and age ≥ 60 years) with disease activity as measured by the Harvey Bradshaw Index (HBI) for CD, and the Simple Clinical Colitis Activity Index (SCCAI) for UC. Disease-specific quality of life was measured by the SIBDQ (Short Inflammatory Bowel Disease Questionnaire). Repeated measures linear regression was used to assess this association over time, adjusted for confounding variables. Results: 609 patients with CD and 310 patients with UC were included. 45% were male, 79% were Caucasian. Mean disease duration was 9.4±9.9 years. 16% were current smokers, 27% were former smokers, and 57% were never smokers. After adjustment for sex, smoking status and disease duration, at index visit, CD patients age 40-59 had higher mean HBI scores (5.7 ± 0.5) and lower mean SIBDQ scores (42.6 ± 1.2), compared to patients over age 60 (HBI 3.8 ± 0.5, SIBDQ 48.0 ± 1.6) (p<0.001). Over time, all CD patients demonstrated improvement in HBI and SIBDQ scores. However, HBI score improvement was less pronounced in the youngest patients (p<0.001), while improvement in SIBDQ scores did not differ between age groups (p=0.38). Patients with UC under age 40 at the index visit had lower SCCAI scores (3.2 ± 0.3) compared to older patients 40-59 (4.0 ± 0.4, p <0.001) (Figure 2) , and higher SIBDQ scores (51.0 + 1.5) compared to patients age 40-59 (SIBDQ 47.1 ± 1.8, p<0.0001). All patients with UC demonstrated improvement in SCCAI and 
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